<h4>Background</h4>Cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, failed to show benefit over lomustine in relapsed glioblastoma. Here, NTRK1 is linked to glioblastoma.